ARROWHEAD PHARMACEUTICALS, INC.
ARROWHEAD PHARMACEUTICALS, INC. (ARWR): 233 pipeline candidates · 10 upcoming catalysts · ~24 mo cash runway · 58 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
24.0 months
1% dilution
Lead: Phase 2
233 candidates
10 upcoming, next in ~75d
0 buys · 32 sells (180d)
A transparent, data-derived signal for ARROWHEAD PHARMACEUTICALS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$11.4B
Cash
$188.5M
Quarterly Burn
$215.0M
Runway
24.0 mo
Revenue
$73.7M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (233 candidates)
| Drug | Phase |
|---|---|
| acetaminophen | Phase 1 |
| Acetaminophen 1000 mg/d | Phase 1 |
| Acetaminophen 325Mg Tab | Phase 4 |
| Acetaminophen 4000 mg/d | Phase 1 |
| Acetaminophen 500Mg Tab | Phase 4 |
| Acetylcysteine | Phase 2 |
| anti-thymocyte globulin | Phase 1 |
| antihistamine | Phase 1 |
| arc-520 | Phase 1 |
| ARC-520 Injection | Phase 2 |
Showing 10 of 233 candidates. Sign up for full pipeline.
Upcoming Catalysts (10)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
436
Total value held
$7.06B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 18,161,519 | $1.14B |
| vanguard capital management llc | 12,064,832 | $756.5M |
| fmr llc | 7,266,652 | $455.6M |
| vanguard portfolio management llc | 7,146,136 | $448.1M |
| state street corp | 6,496,130 | $407.3M |
| geode capital management, llc | 4,278,828 | $274.5M |
| fred alger management, llc | 3,342,493 | $209.6M |
| janus henderson group plc | 2,873,980 | $180.2M |
| baker bros. advisors lp | 1,992,783 | $124.9M |
| susquehanna international group, llp | 1,836,433 | $115.1M |
Showing top 10 of 436 institutional holders of ARROWHEAD PHARMACEUTICALS, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in ARROWHEAD PHARMACEUTICALS, INC.'s pipeline?
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) has 233 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ARROWHEAD PHARMACEUTICALS, INC.'s lead drug candidate?
ARROWHEAD PHARMACEUTICALS, INC.'s most advanced tracked candidate is acetaminophen (Phase 1) for Hepatitis B.
What is ARROWHEAD PHARMACEUTICALS, INC.'s next catalyst?
ARROWHEAD PHARMACEUTICALS, INC.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozsiran in " — expected September 1, 2026.
What is ARROWHEAD PHARMACEUTICALS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ARROWHEAD PHARMACEUTICALS, INC. has approximately 24.0 months of cash runway.
What is ARROWHEAD PHARMACEUTICALS, INC.'s market capitalization?
ARROWHEAD PHARMACEUTICALS, INC.'s market capitalization is approximately $11.4B.
Get the full picture on ARROWHEAD PHARMACEUTICALS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.